Overview of the Safety Profile of CAR-T Therapy
Dr. Mikhael and Dr. Rossi discuss the safety profiles of CAR-T therapies for multiple myeloma, focusing on common and impactful adverse events, comparisons between ide-cel and cilta-cel, alignment with clinical trial data, and how safety considerations influence treatment selection for diverse patient populations.
Video content above is prompted by the following:
- Could you start by giving an overview of the safety profile of CAR-T therapies for multiple myeloma?
- In your experience, what are the most common and impactful adverse events linked to ide-cel and cilta-cel?
- How does this align with the safety data from the KarMMa and CARTITUDE studies?
- How do the safety profiles of ide-cel and cilta-cel compare, and how do they stack up against other CAR-T therapies?
- In what ways do these safety differences impact your choice of CAR-T product for different patient demographics?
Oncology Nurses Provide Patients an Avenue to Supportive Care
November 12th 2019Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.
Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer
March 23rd 2016Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.
Kimberly J. Van Zee on Nomograms Helping in DCIS Treatment Decision-Making
March 18th 2016Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ductal carcinoma in situ (DCIS).
